Primary signet ring cell carcinoma of the pancreatic head: A case report

Abstract

Pancreatic SRCC is a rare, aggressive tumor. Given limited evidence and the risk of side effects, physicians may elect to withhold chemotherapy in select patients, with the exception of neoadjuvant chemotherapy use to facilitate resectability.

Primary Pancreatic Signet Ring Cell Carcinoma: A Case Report and Review of the Literature

“…PPSRCC of the pancreas is a rarely reported subtype of pancreatic adenocarcinoma with only 10 other case reports found in the literature (Table 1). [11][12][13][14][15][16][17][18][19][20] A recent study analyzing surveillance, epidemiology, and end results program (SEER) data found 497 cases of PPSRCC from 1973 to 2018. 5 Over 90% of signet ring cell carcinomas (SRCCs) are gastric cancers, and it is estimated that up to 28.2% of primary gastric cancers are in fact SRCCs.…”

Long-Term Survival by Resection and Adjuvant Chemotherapy With S-1 in Pancreatic Signet Ring Cell Carcinoma: a Case Report With Literature Review

“…According to the study using the Surveillance, Epidemiology, and End Results database from 2000 to 2014, the incidence of pancreatic SRCC is 0.4-0.5% among all cases of pancreatic carcinoma [1]. Among the eight cases reported thus far (Table 1) [4][5][6][7][8][9][10][11], surgical treatment with radical resection, pancreatoduodenectomy, and/or total pancreatomy could be performed in four cases, and there was only one case of borderline-resectable tumor treated with neoadjuvant chemotherapy with gemcitabine.…”

The value of lymph node ratio and total number of lymph nodes examined for resected pancreatic signet ring cell carcinoma: a retrospective cohort study

“…Signet ring cell carcinoma (SRCC) of the pancreas was an exceedingly rare histological subtype of pancreatic cancer, accounting for <1% of pancreatic cancers [14]. Because of the rarity of histological subtype, previous studies always reported the trends of incidence and predictors of pancreatic SRCC.…”

“…For pancreatic SRCC, Kaji et al [12] reported one case that three chemotherapy program was performed following by etoposide and cisplatin (EP therapy),S-1 monotherapy ,albumin-bound paclitaxel and gemcitabine. Dheeraj et al [14] reported that borderline resectable disease should still be considered for neoadjuvant chemotherapy to facilitate potential resectability. Based on these ndings, we thought that it seems chemotherapy based on gemcitabine could be used as a bene cial attempt for the treatment of patients if patients could tolerate the chemotherapy.…”

“…Pancreatic signet ring cell carcinoma (SRCC) is a mucin-secreting adenocarcinoma that contains abundant intracytoplasmic mucin and pushes the nucleus to one side of the cell [1].Signet ring cell carcinoma (SRCC) was mostly occurred in the digestive system and the most common sites are the stomach which account for 15.1-28.2% of primary gastric cancer [2][3][4], occasionally occurring in the colorectal, bile cyst ,breast, bladder, prostate, and lung, whereas primary pancreatic SRCC is extremely rare. Nowadays, just 12 case reports have been published in the English literature of primary SRCC of the pancreas [5][6][7][8][9][10][11][12][13][14][15][16].Previously a large population-based cohort of 497 patients with pancreatic SRCC focused on independent predictors, with the 1-, 2-, and 5-year OS rates of 17%, 9%, and 4%, respectively, which showed a very poor survival [17].…”